IPO Prospects High on the Agenda at BioTrinity

Venue: Newbury Racecourse From Apr 12-14 2010

LONDON, February 24, 2010 - First Quarter of 2010 has shown some early signs of resurgence in life
science IPO's that are already underway or planned. BioTrinity, the UK's
Premier Biopartnering and Investment Conference, will be focusing on the
evidence for early success and the prospects for the remainder of the year
and into 2011 in a series of panel discussions aimed at understanding the
current marketplace, the way companies can maximise their chances of a
successful float and the support the City can give to ensure success.

This is the 4th Annual BioTrinity Conference, which has evolved into the
UK's largest and arguably most successful Biopartnering and Investment
Conference. Because of its success the conference has outgrown the Kassam
Stadium, its home for the past two years and will now take place at the
Newbury Racecourse April 12-14th. A key driver for the success of the
conference has been its focused programme of discussions and panel sessions
tackling the current themes of most interest to the biotechnology industry
and more widely for the life sciences industries in general.

The green shoots of recovery in the life sciences IPO market is a key
consideration for early venture investors as they look for significant
financial inflection points that will generate shareholder value and equip
their companies to take their products and technologies through to
commercialisation. A healthy IPO market is a key element of this and
therefore a focus of the BioTrinity programme for this year.

Investment Banker James Steel, Director of Corporate Finance at KBC Peel
Hunt will lead the discussion helping life sciences companies to understand
the implications of the recent rise in IPO activity on both sides of the
Atlantic. His colleague Senior Healthcare Analyst, Paul Cuddon, will provide
additional input and insights into the City's perception of life science
companies following the downturn and also give views on those areas of life
sciences which are more likely to be IPO candidates on the UK markets over
the coming months. .

These perspectives will be complimented by Ian Paling, CEO and Exec
Chairman of privately-held CellCoTec. As CEO of Corin Group Plc Ian also
guided that company through an IPO in 2002 and subsequently grew it into a
highly regarded publicly quoted orthopaedic company. BioTrinity is also able
to announce that Vernalis' CEO; Ian Garland will join this panel discussion
in the same week that Vernalis plc announced plans to raise GBP30m on the
public markets, These perspectives will be provided by a leading venture
capital house.

As part of it role in fostering partnership building, BioTrinity features
an exclusive pre-conference invitation-only five course wine and tasting
dinner at the Vineyard at Stockcross which is uniquely designed to provide a
convivial forum to encourage investors in the sector to develop syndicates,
exchange knowledge and cooperate on future deals.

    For further information, please contact:

    Jon Rees
    CEO, OBN
    Tel: +44(0)1865-594642

    Anna Dunphy
    De Facto Communications
    Tel: +44(0)20-7861-3838

For further information, please contact: Jon Rees, CEO, OBN, Tel: +44(0)1865-594642; Anna Dunphy, De Facto Communications, Tel: +44(0)20-7861-3838.